Fibrates for Primary Biliary Cholangitis: What’s All the Hype?
Journal Title: Annals of Hepatology - Year 2017, Vol 16, Issue 5
Abstract
Ursodeoxycholic acid is the first-line therapy for primary biliary cholangitis. However, a subset of patients fail to show biochemical response. For these patients, adjuvant therapies are warranted. Obeticholic acid was conditionally approved as a second-line drug. Evidence is building up in favor of fibrates, which are available for off-label use.
Authors and Affiliations
Cynthia Levy
Keywords
Related Articles
- EP ID EP208866
- DOI 10.5604/01.3001.0010.2709
- Views 112
- Downloads 0
Giant hepatocellular adenoma in a previously obese thirteen-year-old boy
Hepatocellular adenoma is an uncommon neoplasm, especially in the childhood age group. We describe a previously obese 13-year-old male with a giant hepatocellular adenoma requiring an extensive hepatic resection. The rel...
It TAK(es) 1 to prevent steatohepatitis and tumorigenesis
Metastatic lymphoepithelioma-like hepatocellular carcinoma: a potential diagnostic pitfall and demonstration of PD-L1 expression
Deep sequencing analysis of microRNA expression in porcine serum-induced hepatic fibrosis rats
Aim. Recent studies have suggested miRNA dysregulation in liver tissue mediates the pathogenesis of various liver diseases especially liver fibrosis, but the microRNA changes during PS-induced hepatic fibrosis are still...
Long term changes in liver histology following treatment of chronic hepatitis C virus
Background and aims. The histologic hallmarks of chronic HCV include inflammation and fibrosis. The impact of interferon therapy on liver histology was evaluated. Material and methods. The study population consisted of 3...